Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: New Pacer--UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

It is my understanding that the current licensing strategy is to focus on selling system licenses to the end user market and a royalty free license to chip manufacturers. I was under the impression that it is still legal to do this and that is what they are doing - focusing on selling system licenses.

<If TPL had licensed or sued the Manufacture of the 212 chip, Sirus would probably not be subject to any infringement. >

Are saying that current licensing strategy is not legal, or you are saying that if Alliacense chose a different strategy than the one employed?

Opty

Share
New Message
Please login to post a reply